JPRN-UMIN000006452已完成2 期
Phase II trial of bi-weekly cetuximab for recurrent or metastatic colorectal cancer - B-CMAb Phase II
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) without active other malignancy 2) without active infection 3) without active brain metastasis 4) without severe pulmonary diseases 5) without HBs Ag 6) without severe heart diseases 7) without pregnancy 8) without prior EGFR inhibitors 9) without other medical condition unacceptable for entry
研究者
相似试验
已完成
2 期
Phase II study of biweekly cetuximab therapy for unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000011361Department of Surgical Oncology Osaka City University10
已完成
2 期
Randomized phase II study of biweekly cetuximab versus panitumumab in patients not combination of irinotecan wild-type KRAS metastatic colorectal cancer following treatment with fluoropyrimidine and oxaliplatin chemotherapyadvanced colorectal cancerJPRN-UMIN000006899Tsukuba Center Clinical Trial Group(TCTG)90
进行中（未招募）
不适用
Ensayo clínico fase II con cetuximab bisemanal en combinación con oxaliplatino, 5-fluorouracilo y ácido folínico (folfox-4) en el tratamiento de primera linea del cáncer colorectal metastásico kras tipo natural.EUCTR2008-006909-16-ESACROSS:Associació Catalana per a la Recerca Oncològica i les seves implicacions sanitàries i Socials
已完成
不适用
Phase II sudy of cetuximab for the treatment of refractory or relapsed multiple myeloma Erbitux for Multiple MyelomACancerISRCTN81968533niversity of Cologne (Germany)33
已完成
不适用
Phase II crinical trial of cetuximab rechallenge with KRAS wild-type unresectable/recurrent colorectal cancerColorectal cancerJPRN-UMIN000009698Okayama Molecular Target-Based Drugs Society for Cancer of the Colon and Rectum25